{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:41:37Z","timestamp":1790757697351,"version":"4.1.0"},"reference-count":24,"publisher":"BMJ","issue":"6","funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess disease burden of chemotherapy-induced peripheral neuropathy (CIPN), which is a common dose-limiting side effect of neurotoxic chemotherapy. Late effects of CIPN may increase with improved cancer survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Olmsted County, Minnesota residents receiving neurotoxic chemotherapy were identified and CIPN was ascertained via text searches of polyneuropathy symptoms in the medical record. Clinical records were queried to collect data on baseline characteristics, risk factors, signs and symptoms of CIPN, medications, impairments and International Classification of Diseases, Ninth Revision (ICD-9) diagnostic codes for all subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 509 individuals with incident exposure to an inclusive list of neurotoxic chemotherapy agents between 2006 and 2008 were identified. 268 (52.7%) of these individuals were determined to have CIPN. The median time from incident exposure to first documented symptoms was 71 days. Patients with CIPN received a neuropathy ICD-9 diagnosis in only 37 instances (13.8%). Pain symptoms and use of pain medications were observed more often in patients with CIPN. Five-year survival was greater in those with CIPN (55.2%) versus those without (36.1%). Those with CIPN surviving greater than 5 years (n=145) continued to have substantial impairments and were more likely to be prescribed opioids than those without CIPN (OR 2.0, 1.06\u20133.69).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Results from our population-based study are consistent with previous reports of high incidence of CIPN in the first 2\u2009years following incident exposure to neurotoxic chemotherapeutic agents, and its association with significant pain symptomatology and accompanied long-term opioid use. Increased survival following exposure to neurotoxic chemotherapy and its long-term disease burden necessitates further study among survivors.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2017-317215","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T06:22:19Z","timestamp":1518157339000},"page":"636-641","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":146,"title":["Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort"],"prefix":"10.1136","volume":"89","author":[{"given":"Arya","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Matthew","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L","family":"Mauermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J","family":"Windebank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6760-3859","authenticated-orcid":false,"given":"Nathan P","family":"Staff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,2,8]]},"reference":[{"key":"2020050722301641000_89.6.636.1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann Neurol"},{"key":"2020050722301641000_89.6.636.2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2020050722301641000_89.6.636.3","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1007\/s00520-016-3329-5","article-title":"Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment","volume":"24","author":"Zanville","year":"2016","journal-title":"Support Care Cancer"},{"key":"2020050722301641000_89.6.636.4","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.clinph.2015.07.022","article-title":"Balance impairments and neuromuscular changes in breast cancer patients with chemotherapy-induced peripheral neuropathy","volume":"127","author":"Kneis","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"2020050722301641000_89.6.636.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1127-7"},{"key":"2020050722301641000_89.6.636.6","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000149522.32823.EA"},{"key":"2020050722301641000_89.6.636.7","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys195"},{"key":"2020050722301641000_89.6.636.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020"},{"key":"2020050722301641000_89.6.636.9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2015.10.017","article-title":"Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: a subset analysis from a randomised phase III trial (MPACT)","volume":"52","author":"Goldstein","year":"2016","journal-title":"Eur J Cancer"},{"key":"2020050722301641000_89.6.636.10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2014.12.041","article-title":"Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients","volume":"349","author":"Johnson","year":"2015","journal-title":"J Neurol Sci"},{"key":"2020050722301641000_89.6.636.11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.clcc.2017.03.013","article-title":"Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer","volume":"16","author":"Raphael","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"2020050722301641000_89.6.636.12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp509"},{"key":"2020050722301641000_89.6.636.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2012.05.002"},{"key":"2020050722301641000_89.6.636.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1667-5"},{"key":"2020050722301641000_89.6.636.15","doi-asserted-by":"publisher","DOI":"10.1159\/000442527"},{"key":"2020050722301641000_89.6.636.16","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2015.16.17.7603"},{"key":"2020050722301641000_89.6.636.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2346"},{"key":"2020050722301641000_89.6.636.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8446"},{"key":"2020050722301641000_89.6.636.19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamaneurol.2017.0486","article-title":"Association of long-term opioid therapy with functional status, adverse outcomes, and mortality among patients with polyneuropathy","volume":"74","author":"Hoffman","year":"2017","journal-title":"JAMA Neurol"},{"key":"2020050722301641000_89.6.636.20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001492"},{"key":"2020050722301641000_89.6.636.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198802113180604"},{"key":"2020050722301641000_89.6.636.22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/0885713x9000500304","article-title":"Accuracy of ICD-9-CM codes in identifying reportable communicable diseases","volume":"5","author":"Campos-Outcalt","year":"1990","journal-title":"Qual Assur Util Rev"},{"key":"2020050722301641000_89.6.636.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1990.tb06450.x"},{"key":"2020050722301641000_89.6.636.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2005.00444.x"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2017-317215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:09:14Z","timestamp":1601057354000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2017-317215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,8]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,5,24]]},"published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1136\/jnnp-2017-317215"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2017-317215","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,8]]}}}